Erdafitinib is an oral FGFR tyrosine kinase inhibitor developed for molecularly selected cancers, particularly urothelial carcinoma with susceptible FGFR3 alterations.
Molecular pharmacology
FGFR proteins are receptor tyrosine kinases involved in cellular signaling. Erdafitinib inhibits FGFR-mediated signaling and is intended to interfere with abnormal signaling caused by susceptible FGFR alterations.
Pharmacokinetics
Erdafitinib has a relatively long effective half-life. The original FDA clinical pharmacology assessment reported a mean effective half-life of approximately 59 hours.
Metabolism
Erdafitinib is primarily metabolized through CYP2C9 and CYP3A4. The FDA assessment estimated contributions of approximately 39% and 20%, respectively, to total clearance.
Elimination
Following a radiolabeled dose in the FDA pharmacology assessment, approximately 69% of the administered dose was recovered in feces and approximately 19% in urine, with unchanged drug accounting for portions of both routes.
Pharmacokinetic considerations
The original FDA assessment did not identify clinically meaningful pharmacokinetic trends based on age, sex, race, body weight, mild or moderate renal impairment, or mild hepatic impairment. Pharmacokinetics in severe renal impairment, dialysis and moderate or severe hepatic impairment were not established in that assessment.
Biomarker selection
Current U.S. treatment selection requires identification of susceptible FGFR3 genetic alterations using an FDA-approved companion diagnostic.
THOR phase 3 evidence
The THOR trial randomized 266 patients with advanced or metastatic urothelial carcinoma and FGFR alterations to erdafitinib or chemotherapy. Median overall survival was 12.1 months with erdafitinib versus 7.8 months with chemotherapy. Median progression-free survival was 5.6 versus 2.7 months.
Interpretation of clinical evidence
Clinical trial outcomes describe groups of selected patients. They cannot establish that an individual patient will experience the same response or survival outcome.